vs
OneStream, Inc.（OS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
OneStream, Inc.的季度营收约是再鼎医药的1.3倍（$163.7M vs $127.1M），OneStream, Inc.同比增速更快（23.6% vs 17.1%），OneStream, Inc.自由现金流更多（$25.6M vs $-26.7M），过去两年OneStream, Inc.的营收复合增速更高（21.8% vs 20.8%）
Blue Stream面向美国佛罗里达州科勒尔斯普林斯、韦斯顿两地的居民及商业客户，提供有线电视、有线固话、数字录像服务，以及最高速率达1G的宽带互联网接入服务，深耕当地通信市场，为用户提供稳定可靠的多元通信解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
OS vs ZLAB — 直观对比
营收规模更大
OS
是对方的1.3倍
$127.1M
营收增速更快
OS
高出6.5%
17.1%
自由现金流更多
OS
多$52.3M
$-26.7M
两年增速更快
OS
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $163.7M | $127.1M |
| 净利润 | $999.0K | — |
| 毛利率 | 69.8% | 51.0% |
| 营业利润率 | -3.2% | -54.6% |
| 净利率 | 0.6% | — |
| 营收同比 | 23.6% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSZLAB
| Q4 25 | $163.7M | $127.1M | ||
| Q3 25 | $154.3M | $115.4M | ||
| Q2 25 | $147.6M | $109.1M | ||
| Q1 25 | $136.3M | $105.7M | ||
| Q4 24 | $132.5M | $108.5M | ||
| Q3 24 | $129.1M | $101.8M | ||
| Q2 24 | $117.5M | $100.1M | ||
| Q1 24 | $110.3M | $87.1M |
净利润OSZLAB
| Q4 25 | $999.0K | — | ||
| Q3 25 | $-8.8M | $-36.0M | ||
| Q2 25 | $-18.4M | $-40.7M | ||
| Q1 25 | $-24.0M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-171.9M | $-41.7M | ||
| Q2 24 | $-7.8M | $-80.3M | ||
| Q1 24 | $-5.0M | $-53.5M |
毛利率OSZLAB
| Q4 25 | 69.8% | 51.0% | ||
| Q3 25 | 68.1% | 59.5% | ||
| Q2 25 | 68.6% | 60.6% | ||
| Q1 25 | 68.0% | 63.6% | ||
| Q4 24 | 66.8% | 61.5% | ||
| Q3 24 | 50.1% | 64.1% | ||
| Q2 24 | 68.5% | 64.9% | ||
| Q1 24 | 69.1% | 61.4% |
营业利润率OSZLAB
| Q4 25 | -3.2% | -54.6% | ||
| Q3 25 | -11.3% | -42.3% | ||
| Q2 25 | -21.8% | -50.3% | ||
| Q1 25 | -29.3% | -53.3% | ||
| Q4 24 | -35.8% | -62.6% | ||
| Q3 24 | -197.6% | -66.6% | ||
| Q2 24 | -9.8% | -76.0% | ||
| Q1 24 | -4.9% | -80.7% |
净利率OSZLAB
| Q4 25 | 0.6% | — | ||
| Q3 25 | -5.7% | -31.2% | ||
| Q2 25 | -12.5% | -37.3% | ||
| Q1 25 | -17.6% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -133.1% | -40.9% | ||
| Q2 24 | -6.7% | -80.2% | ||
| Q1 24 | -4.5% | -61.4% |
每股收益（稀释后）OSZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-1.06 | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $693.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $504.7M | $715.5M |
| 总资产 | $1.0B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OSZLAB
| Q4 25 | $693.6M | $689.6M | ||
| Q3 25 | $653.9M | $717.2M | ||
| Q2 25 | $652.1M | $732.2M | ||
| Q1 25 | $593.9M | $757.3M | ||
| Q4 24 | $544.2M | $779.7M | ||
| Q3 24 | $495.5M | $616.1M | ||
| Q2 24 | $140.5M | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益OSZLAB
| Q4 25 | $504.7M | $715.5M | ||
| Q3 25 | $472.1M | $759.9M | ||
| Q2 25 | $458.2M | $791.7M | ||
| Q1 25 | $412.9M | $810.8M | ||
| Q4 24 | $386.2M | $840.9M | ||
| Q3 24 | $458.2M | $667.7M | ||
| Q2 24 | $97.5M | $704.2M | ||
| Q1 24 | $102.5M | $762.2M |
总资产OSZLAB
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $949.4M | $1.2B | ||
| Q2 25 | $910.5M | $1.2B | ||
| Q1 25 | $867.3M | $1.2B | ||
| Q4 24 | $823.2M | $1.2B | ||
| Q3 24 | $750.1M | $985.3M | ||
| Q2 24 | $379.7M | $987.4M | ||
| Q1 24 | — | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $25.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 15.7% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 25.79× | — |
| 过去12个月自由现金流最近4个季度 | $95.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流OSZLAB
| Q4 25 | $25.8M | $-26.0M | ||
| Q3 25 | $5.0M | $-32.0M | ||
| Q2 25 | $29.7M | $-31.0M | ||
| Q1 25 | $36.2M | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | $2.4M | $-26.8M | ||
| Q2 24 | $8.1M | $-42.2M | ||
| Q1 24 | $25.5M | $-90.1M |
自由现金流OSZLAB
| Q4 25 | $25.6M | $-26.7M | ||
| Q3 25 | $4.8M | $-35.0M | ||
| Q2 25 | $29.4M | $-33.9M | ||
| Q1 25 | $35.8M | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | $1.3M | $-28.2M | ||
| Q2 24 | $7.7M | $-42.9M | ||
| Q1 24 | $24.9M | $-91.1M |
自由现金流率OSZLAB
| Q4 25 | 15.7% | -21.0% | ||
| Q3 25 | 3.1% | -30.4% | ||
| Q2 25 | 19.9% | -31.1% | ||
| Q1 25 | 26.3% | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | 1.0% | -27.7% | ||
| Q2 24 | 6.6% | -42.9% | ||
| Q1 24 | 22.5% | -104.5% |
资本支出强度OSZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
现金转化率OSZLAB
| Q4 25 | 25.79× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
